Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Jul 14, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of two oral medications, vismodegib and sonidegib, for treating different types of skin cancer known as basal cell carcinoma. These types of cancer can be locally advanced or metastatic, and the study also includes patients with a condition called Gorlin syndrome, which causes multiple basal cell tumors. The goal is to compare these two medications to see how well they work and to gather more information about their side effects and impact on patients' quality of life.
Anyone diagnosed with locally advanced or metastatic basal cell carcinoma or Gorlin syndrome may be eligible to participate, regardless of their age or gender. Participants will receive one of the treatments and their progress will be monitored. The researchers will look at how long patients remain without disease progression and collect information about any side effects they may experience. This study is important as it aims to provide valuable insights into the best treatment options for patients with these skin cancers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women
- • All ages
- • Diagnosed with locally advanced basal cell carcinoma (laBCC), metastatic basal cell carcinoma (mBCC), multiple basal cell carcinomas or Gorlin syndrome
- • Use of oral hedgehog inhibitor vismodegib or sonidegib
- Exclusion Criteria:
- • None
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Utrecht, , Netherlands
Leiden, Zuid Holland, Netherlands
Rotterdam, Zuid Holland, Netherlands
Nijmegen, Gelderland, Netherlands
Amsterdam, Noord Holland, Netherlands
Maastricht, Limburg, Netherlands
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
K Mosterd, MD, PhD
Principal Investigator
Maastricht University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials